Premier Biomedical, Inc. (BIEI)

Premier Biomedical, Inc. (BIEI) — VMCI valuation read

Headline read on BIEI: VMCI of 32/100 versus a Healthcare sector median of 50. The 18-point below-median position is what makes Premier Biomedical, Inc. a relative-value laggard in the mid-cap cohort, before any pillar-level review.

Form 4 filings on BIEI: zero in the trailing 30 days. The absence of insider transactions is itself a data point, just a low-information one. The thesis runs on financials and price action until that changes.

**Investor frame.** Three reads on BIEI: value (BIEI trades at 17.0x earnings, 6% below the Healthcare median of 18.0x), quality (ROIC of 15.0% sits 5.0pp above the Healthcare median (10.0%)), and risk (net debt to EBITDA of 2.4x is the rate-sensitivity line to watch). The value read also implies an EV/EBITDA gap of +4.0x against the Healthcare 12.0x baseline.

BIEI fell 4.0% over the trailing 7 days, with a -2.8% read on a 30-day basis.